For retail investors tracking srne stock (Sorrento Therapeutics), the financial journey has been an incredibly complex, highly stressful, and controversial saga. Once valued as a multi-billion dollar biotechnology powerhouse during the height of the COVID-19 pandemic, the company's trajectory took a sharp downturn, leading to a Chapter 11 bankruptcy filing in early 2023.
If you currently hold shares of Sorrento Therapeutics—which trade under the tickers SRNE and SRNEQ on the Over-the-Counter (OTC) markets—you are likely seeking clear, objective answers. What is the current status of the stock? Can you still trade it? What happens to the restricted Scilex Holding Company (SCLX) dividend shares that remain locked in your brokerage account? And what is the role of Vivasor, the private company that absorbed Sorrento's clinical assets?
This comprehensive, investigative guide breaks down the reality of srne stock. We will analyze the official court dockets, look at the staggering professional fees that depleted the estate, examine the ongoing multi-million dollar lawsuits, and detail exactly where retail shareholders stand in this complex financial puzzle.
The Rise and Fall of Sorrento Therapeutics
To understand the current state of srne stock, it is essential to look back at the aggressive corporate expansions and legal battles that precipitated its collapse. Co-founded by Dr. Henry Ji in 2006, Sorrento Therapeutics positioned itself as a highly ambitious clinical-stage biopharmaceutical developer. Its pipeline was remarkably diverse, spanning oncology, non-opioid pain therapeutics, and immunology.
Sorrento's valuation skyrocketed during the 2020 biotech boom. Dr. Ji pivoted the company heavily toward COVID-19 diagnostics and therapeutics. Driven by high-profile media appearances and bold declarations—such as claiming the company had discovered a 'cure' for COVID-19 through its antibody pipeline—Sorrento became a darling of retail investors and a prime target for institutional short sellers. The stock price reached all-time highs, fueled by retail enthusiasm and a pipeline that promised rapid diagnostic tests (like COVISTIX) and advanced cellular therapies.
However, Sorrento’s rapid expansion was accompanied by an unsustainable cash burn rate. The company funded its research, acquisitions, and operations through continuous share dilution and high-interest debt. The structural fragility of this model was exposed when Sorrento entered a fierce legal battle with billionaire Patrick Soon-Shiong and his related pharmaceutical entities. The dispute, which centered on allegations of a 'catch-and-kill' scheme involving the cancer drug Cynviloq, culminated in a massive arbitration judgment against Sorrento.
Facing a sudden liquidity crisis and unable to pay the multi-million dollar settlement, Sorrento Therapeutics filed for voluntary Chapter 11 bankruptcy protection on February 13, 2023. This filing immediately triggered the delisting of srne stock from the NASDAQ, relegating the shares to the highly volatile OTC markets under the ticker SRNEQ.
The Bankruptcy Proceedings: $63 Million in Fees and No Creditor Distributions
Sorrento's Chapter 11 case, administered under Case No. 23-90085 in the U.S. Bankruptcy Court for the Southern District of Texas, quickly became one of the most controversial bankruptcy proceedings in the biopharma sector. Retail investors watched in disbelief as the company's remaining cash and assets were steadily consumed by administrative and legal fees.
According to the official Post-Confirmation Report filed in the Sorrento bankruptcy on January 29, 2026 (UST Form 11-PCR), the cost of administering the estate has been astronomically high. Since the Plan Effective Date of April 10, 2024, the bankruptcy court had approved over $63.9 million in total professional fees. High-profile bankruptcy professionals and legal advisory firms claimed the vast majority of these payouts:
- Latham & Watkins: $27.3 million
- M3 Advisory: $12.3 million
- Moelis & Company: $6.0 million
- Stretto (Claims Agent): $2.4 million
- Jackson Walker: $1.38 million
While tens of millions of dollars flowed out of the estate to pay lawyers, restructuring advisors, and consultants, the recovery rate for actual creditors and shareholders remained at absolute zero. The January 2026 court report confirmed that not a single dollar had been distributed to administrative claims, secured claims, priority claims, general unsecured claims, or equity interests.
The stark reality is that Sorrento's bankruptcy did not result in a traditional restructuring that preserved shareholder value. Instead, the process functioned as a systematic asset liquidation where the legal fees consumed virtually all liquid assets, leaving the remaining corporate shell empty.
The Reorganization Plan: How Vivasor Acquired Sorrento's Assets
Rather than emerging from Chapter 11 as an independent, publicly traded operating company, Sorrento underwent a transaction that effectively transferred its entire operating business to a private entity. Under the court-approved reorganization and liquidation plan that went effective on April 10, 2024, Sorrento sold substantially all of its remaining clinical assets, intellectual property, and subsidiaries to Vivasor, Inc.
Vivasor, Inc. is a private Delaware corporation founded and led by Sorrento's former CEO and Chairman, Dr. Henry Ji. Vivasor acquired these assets for a purchase price consisting of $15.5 million in cash and a $5 million promissory note, alongside the assumption of certain liabilities. This transaction included highly valued development pipelines, such as the non-opioid pain therapeutic Resiniferatoxin (RTX), which continues to see active patent development for indications like osteoarthritis, prostate cancer, and Parkinson's disease.
For retail holders of srne stock, this asset transfer was a devastating blow. The valuable drug pipelines and intellectual property that originally attracted investors to Sorrento are now owned by Vivasor, a private entity in which public shareholders have no equity stake.
Meanwhile, the legacy public entity was converted into a Liquidating Trust, tasked solely with wrapping up outstanding litigation, resolving claims, and winding down the remaining corporate shell. In short, Sorrento's operating business survived under a new private banner led by its original founder, while public stock holders were left holding shares of a non-operating liquidating shell.
Trading SRNE Stock Today: The Expert Market Reality
If you look up the quote for srne stock today on OTC markets, you will find it trading at a nominal price of around $0.0005 to $0.0006 per share. This represents a near-total loss of value from its pre-bankruptcy trading levels. However, the price is only part of the problem; the actual mechanics of trading the stock have become virtually impossible for average retail investors.
The stock is currently categorized under the 'Expert Market' by the OTC Markets Group. The Expert Market is a highly restricted tier of the OTC market designed for professional and institutional investors. Securities are placed on the Expert Market when they are no longer eligible for proprietary broker-dealer public quotations under SEC Rule 15c2-11. This typically occurs because the issuer is delinquent in filing its mandatory periodic financial reports with the SEC.
For retail investors, trading on the Expert Market carries massive hurdles:
- No Public Quotes: Broker-dealers are prohibited from publishing public buy and sell quotes. Any quotes you see reflect unsolicited customer orders.
- Restricted Buying: Most standard retail brokerages (such as Robinhood, Fidelity, or Charles Schwab) do not allow retail customers to purchase Expert Market securities. They only permit 'liquidation-only' orders, meaning you can sell existing shares but cannot buy new ones.
- Illiquidity and Wide Spreads: Because there is no active market-making, the bid-ask spreads are incredibly wide, and executing a trade can take days or fail entirely due to a lack of buyers.
While some retail investors on online forums like Reddit's r/BANDOFBROTHERSOFSRNE discuss technical charts and short-interest ratios, the institutional reality is that the stock represents a liquidating shell with no active business operations, zero cash flow, and no path to return to a major stock exchange like the NASDAQ.
The Legal Battleground: The Liquidating Trust's $100 Million Lawsuit
Although the operating assets of Sorrento are now gone, the Liquidating Trust remains highly active in the bankruptcy courts. Under the leadership of Liquidating Trustee David Weinhoffer, the trust has launched aggressive legal campaigns to recover value for the estate's unpaid creditors.
The most significant of these actions is an adversary proceeding filed in July 2025 against Sorrento's former directors and officers, including Dr. Henry Ji. The complaint alleges that the former leadership breached their fiduciary duties, causing at least $100 million in damages to Sorrento’s creditors.
The core of the Trustee's lawsuit centers on what is described as a 'duplicitous transfer' of value just one month before Sorrento filed for bankruptcy. In early 2023, Sorrento distributed roughly half of its total corporate value to its shareholders in the form of an extraordinary stock dividend consisting of shares of Scilex Holding Company (SCLX), a majority-owned subsidiary of Sorrento. The Liquidating Trustee argues that this gratuitous distribution of Scilex shares was a constructive fraudulent transfer designed to strip valuable, liquid assets out of Sorrento's estate and place them beyond the reach of creditors right before declaring insolvency.
While the lawsuit represents a major battle for the Liquidating Trust, retail holders of srne stock must understand the legal priority of claims. Under bankruptcy law, any funds recovered from this $100 million lawsuit will not go directly to public shareholders. Instead, they must be distributed according to the absolute priority rule:
- Administrative Expenses: Unpaid professional fees, legal bills, and trustee costs.
- Secured and Priority Creditors: Lenders and tax authorities.
- General Unsecured Creditors: Trade vendors, suppliers, and litigation claimants.
- Equity Holders (SRNE Stock): Retail shareholders.
Because the administrative and unsecured claims run into the tens of millions of dollars, the likelihood of any litigation recovery trickling down to equity holders is extremely remote. The lawsuit is a battle fought for the benefit of creditors and the lawyers administering the trust, not a mechanism for restoring value to Sorrento's stock.
The Scilex (SCLX) Dividend Saga and Endless Lockups
One of the most unique and frustrating aspects of the Sorrento bankruptcy for retail investors is the saga of the Scilex Holding Company (SCLX) dividend stock. In an attempt to reward loyal shareholders and defend against short-selling, Sorrento distributed millions of SCLX shares to its stock holders as a dividend in early 2023. These shares appeared in investors' brokerage accounts but were immediately locked up, meaning they could not be sold or transferred.
The bankruptcy court has repeatedly extended this lockup period. These extensions—stretching through 2024, 2025, and well into 2026—were implemented to prevent a sudden flood of Scilex shares into the open market. A massive sell-off would collapse the stock price of Scilex, which Sorrento's estate and the Liquidating Trust have continually relied upon as collateral or as an asset to liquidate to pay off creditors.
While Sorrento itself is a liquidating shell, Scilex Holding Company remains an active, publicly traded company (NASDAQ: SCLX) focused on non-opioid pain management therapeutics (such as ZTlido, ELYXYB, and Gloperba). Dr. Henry Ji continues to serve as Scilex's CEO and President, having assumed the role in August 2025 following the resignation of Jaisim Shah. This leadership overlap has fueled immense controversy among retail investors, many of whom feel that Ji successfully transitioned his focus and the company's best assets to Scilex and Vivasor, leaving Sorrento shareholders with nothing but restricted dividend shares and worthless shell stock.
For investors holding these 'restricted' Scilex dividend shares, the primary question is when they will finally become freely tradable. Until the Liquidating Trust resolves its outstanding litigation—specifically the fraudulent transfer claims surrounding the dividend itself—and the bankruptcy court officially lifts the lockup orders, those SCLX shares will remain frozen in brokerage accounts, unable to be liquidated.
Frequently Asked Questions About SRNE Stock
Can I still sell my SRNE stock?
Yes, but with major limitations. Because SRNE is traded on the Expert Market, most standard retail brokers only allow 'liquidation-only' orders. This means you can sell your existing shares, but you cannot buy more. However, due to the extreme lack of liquidity and the absence of active market makers, finding a buyer at any price can be very difficult, and you may receive only a fraction of a cent per share.
Will Sorrento Therapeutics ever return to the NASDAQ?
No. Sorrento Therapeutics sold substantially all of its operating assets and pipelines to Vivasor, Inc. in April 2024 and transitioned into a Liquidating Trust. The company has no active business operations, no revenue, and is currently being wound down. There is no corporate mechanism or financial foundation for the company to ever relist on a major stock exchange.
What happens to my restricted Scilex (SCLX) dividend shares?
Those shares are currently subject to court-ordered trading restrictions and lockup extensions. They remain in your brokerage account as restricted equity. Until the Liquidating Trust's litigation is settled and the bankruptcy court formally lifts the lockup order, you cannot sell, transfer, or trade these shares. They represent potential value, but that value is currently frozen.
Who is David Weinhoffer?
David Weinhoffer is the court-appointed Liquidating Trustee of the Sorrento Therapeutics Liquidating Trust. His role is to manage the remaining assets, resolve outstanding creditor claims, and pursue litigation (such as the $100 million lawsuit against former officers and directors) to recover funds for the estate's unpaid creditors.
Is SRNE the same as SCLX?
No. Sorrento Therapeutics (SRNE) and Scilex Holding Company (SCLX) are two entirely different legal entities. Sorrento was once the majority owner of Scilex. While Sorrento is now in liquidation and its stock is virtually worthless, Scilex remains an active, operating biotech company traded on the NASDAQ. However, the two companies remain deeply entangled due to shared leadership (Dr. Henry Ji) and ongoing bankruptcy litigation regarding the Scilex dividend.
Conclusion
The saga of srne stock serves as a cautionary tale for retail investors in the highly volatile biotechnology sector. What began as a promising COVID-era high-flyer ended in a highly complex bankruptcy that wiped out equity holders while leaving corporate insiders in control of the valuable drug pipelines under a private banner.
For current shareholders, the hard reality is that legacy Sorrento stock (SRNE/SRNEQ) has no viable path to recovery. The operating assets are gone, the company is in liquidation, and any potential litigation recoveries will be consumed by tens of millions of dollars in outstanding administrative fees and creditor claims. The only potential silver lining remains the restricted Scilex (SCLX) dividend shares, but even their fate is tied to the complex, ongoing legal battles of the Liquidating Trust. Investors should approach any claims of a 'miracle recovery' for SRNE with extreme skepticism and focus on the cold, documented facts of the bankruptcy court dockets.
